CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 180 enrolled
Drug / intervention
Sildenafil Citrate +1 moredrug
Likely dose
Sildenafil Citrate 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00517933
NCT00517933Phase 3Completed
CompareCT.gov

Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis

Duke University·interventional·Posted Aug 17, 2007·Updated Jun 24, 2015

In Brief

A Phase 3 clinical trial evaluating Sildenafil Citrate and Placebo for Pulmonary Fibrosis and Hypertension, Pulmonary. Completed, enrolled 180 participants across 13 sites.

Detailed Summary

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that affects an individual's ability to breathe. This study will evaluate the effectiveness of sildenafil, a medication that increases blood flow to the lungs, at improving breathing function, exercise capacity, and quality of life in people with advanced IPF.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Fibrosis, Hypertension, Pulmonary
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), Pfizer

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 17, 2007
Enrollment StartAug 1, 2007
Primary CompletionMay 1, 2009
Study CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.9 years ago

Interventions

Sildenafil Citratedrug

Sildenafil citrate (20mg 3 times a day \[TID\] orally for 12 weeks followed by 20mg TID open-label sildenafil for an additional 12 weeks)

Placeboother

Placebo (20mg TID orally for 12 weeks followed by 20mg open-label sildenafil for 12 weeks)